

Primary Mitochondrial Diseases Workshop Agenda

(virtual public workshop) May 22, 2025

10am Welcome & Opening Remarks

Susan C. Winckler, RPh, Esq., Reagan-Udall Foundation for the FDA

10:05am FDA Opening Remarks

Catherine Pilgrim-Grayson, MD, MPH, Center for Drug Evaluation and Research, FDA

10:10am Setting the Stage: A Variety of Perspectives

Michio Hirano, MD, Columbia University Medical Center

Clinical Trial Design and Implementation: Patient Population Considerations

Anna Choe, MD, MPH, Center for Drug Evaluation and Research, FDA

Primary Mitochondrial Disease Drug Development

Reenie McCarthy, JD, Stealth BioTherapeutics

11:05am Reactor Panel

- Marni Falk, MD, Children's Hospital of Philadelphia & University of Pennsylvania Perelman School of Medicine
- Brian Tseng, MD, PhD, The POLG Foundation
- Philip Yeske, PhD, United Mitochondrial Disease Foundation

11:35am 10-minute Break

11:45am Selecting Patient-focused Outcomes & Statistical Considerations

- Naomi Knoble, PhD, Center for Drug Evaluation and Research, FDA
- Yan Wang, PhD, Center for Drug Evaluation and Research, FDA

12:15pm Clinical Outcome Assessment Example

Amel Karaa, MD, Massachusetts General Hospital & Harvard Medical School

12:30pm Reactor Panel

- Kasey Woleben, Cure Mito Foundation
- Zarazuela Zolkipli-Cunningham, MBChB, MRCP, Children's Hospital of Philadelphia & University of Pennsylvania Perelman School of Medicine

1:00pm LUNCH

1:30pm Current Approaches, Challenges, and Opportunities

- Chad Glasser, PharmD, MPH, Tisento Therapeutics
- Magnus Hansson, MD, PhD, Abliva AB, A Member of Pharming Group

Q&A (20 min)

2:30pm Using What We've Learned To Move Forward

- Jason Colquitt, Across Healthcare
- Amel Karaa, MD, Massachusetts General Hospital & Harvard Medical School
- Kerry Jo Lee, MD, Center for Drug Evaluation and Research, FDA
- Sophia Zilber, Lived Experience Perspective

3:30pm Closing Remarks & Adjourn